Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Wray

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The Lancet. Haematology|September 24, 2021
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trialsAllison Barz Leahy, Haley Newman, Yimei Li, et al.
Blood Advances|November 20, 2024
Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapyBarbara D Friedes, Amanda M DiNofia, Emma Iannone, et al.
Blood|December 6, 2021
Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapyAllison Barz Leahy, Kaitlin J Devine, Yimei Li, et al.
Blood|November 9, 2022
Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapyHaley Newman, Yimei Li, Hongyan Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2021
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical TrialStephan Kadauke, Regina M Myers, Yimei Li, et al.
Haematologica|November 27, 2025
Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemiaRegina M Myers, Yimei Li, Hongyan Liu, et al.
Blood Advances|February 22, 2024
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemiaRegina M Myers, Kaitlin Devine, Yimei Li, et al.
Journal for Immunotherapy of Cancer|April 17, 2025
CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapyRegina M Myers, Amanda M DiNofia, Yimei Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2021
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic LeukemiaRegina M Myers, Yimei Li, Allison Barz Leahy, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The Lancet. Haematology|September 24, 2021
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trialsAllison Barz Leahy, Haley Newman, Yimei Li, et al.
Blood Advances|November 20, 2024
Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapyBarbara D Friedes, Amanda M DiNofia, Emma Iannone, et al.
Blood|December 6, 2021
Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapyAllison Barz Leahy, Kaitlin J Devine, Yimei Li, et al.
Blood|November 9, 2022
Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapyHaley Newman, Yimei Li, Hongyan Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2021
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical TrialStephan Kadauke, Regina M Myers, Yimei Li, et al.
Haematologica|November 27, 2025
Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemiaRegina M Myers, Yimei Li, Hongyan Liu, et al.
Blood Advances|February 22, 2024
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemiaRegina M Myers, Kaitlin Devine, Yimei Li, et al.
Journal for Immunotherapy of Cancer|April 17, 2025
CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapyRegina M Myers, Amanda M DiNofia, Yimei Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2021
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic LeukemiaRegina M Myers, Yimei Li, Allison Barz Leahy, et al.
Pageof 2